Clinical Trial Detail

NCT ID NCT02143726
Title Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Alliance for Clinical Trials in Oncology
Indications

thyroid cancer

Therapies

Sorafenib

Everolimus

Age Groups: adult

No variant requirements are available.